Analysts Offer Predictions for CRBU FY2029 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Equities research analysts at Brookline Capital Management issued their FY2029 EPS estimates for shares of Caribou Biosciences in a research report issued to clients and investors on Monday, January 6th. Brookline Capital Management analyst L. Cann expects that the company will post earnings of $16.92 per share for the year. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share.

A number of other analysts also recently issued reports on CRBU. Bank of America dropped their price target on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday. HC Wainwright reissued a “buy” rating and issued a $9.00 price target on shares of Caribou Biosciences in a research note on Friday, November 15th. Finally, Citigroup decreased their price target on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, November 26th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $10.33.

Caribou Biosciences Stock Performance

NASDAQ:CRBU opened at $1.87 on Wednesday. The firm has a market capitalization of $169.33 million, a price-to-earnings ratio of -1.13 and a beta of 2.34. The stock has a fifty day moving average of $2.03 and a 200 day moving average of $2.00. Caribou Biosciences has a 52-week low of $1.50 and a 52-week high of $8.33.

Caribou Biosciences (NASDAQ:CRBU) last issued its earnings results on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.06. The business had revenue of $2.02 million during the quarter, compared to the consensus estimate of $3.37 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%.

Institutional Investors Weigh In On Caribou Biosciences

Hedge funds have recently made changes to their positions in the business. PFM Health Sciences LP raised its position in Caribou Biosciences by 5.5% in the 3rd quarter. PFM Health Sciences LP now owns 4,306,671 shares of the company’s stock worth $8,441,000 after purchasing an additional 223,299 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Caribou Biosciences by 25.7% during the second quarter. Dimensional Fund Advisors LP now owns 2,623,283 shares of the company’s stock valued at $4,302,000 after buying an additional 536,162 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Caribou Biosciences by 6.5% in the third quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock worth $3,980,000 after buying an additional 124,782 shares during the period. FMR LLC lifted its stake in shares of Caribou Biosciences by 7.4% in the 3rd quarter. FMR LLC now owns 1,581,493 shares of the company’s stock valued at $3,100,000 after acquiring an additional 109,606 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in Caribou Biosciences during the 2nd quarter valued at about $2,432,000. 77.51% of the stock is currently owned by institutional investors.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.